7 completed, 2 unknown, 1 terminated. 6 Phase 2, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
Follow Paraganglioma, Extra-Adrenal: new trials by email Literature Review of Paraganglioma, Extra-Adrenal trials Research Report on Paraganglioma, Extra-Adrenal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment Penpulimab - Pheochromocytoma, Metastatic, Pheochromocytoma Malignant | Phase 2 | Unknown | Peking Union Medical College Hospital | 5 | 2023-04-01 | 2023-06-02 |
| Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients Contrast-enhanced ultrasound(CEUS) - Pheochromocytoma, Metastatic, Ultrasonography | Unknown | Peking Union Medical College Hospital | 20 | 2023-03-01 | 2023-08-29 | |
| The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma anlotinib hydrochloride - Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma | Phase 2 | Completed | Peking Union Medical College Hospital | 27 | 2021-04-30 | 2024-06-12 |
| The Efficacy and Safety of Temozolomide in Patients With MPPGL Temozolomide capsule - Pheochromocytoma, Metastatic, Paraganglioma, Malignant | Phase 2 | Completed | Peking Union Medical College Hospital | 62 | 2019-10-01 | 2023-05-15 |
| Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment - Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma | Phase 2 | Completed | Mayo Clinic | 3 | 2017-05-31 | 2024-02-20 |
| Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer Computed Tomography, Dual X-ray Absorptiometry, Physical Examination - Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma | Not applicable | Completed | M.D. Anderson Cancer Center | 23 | 2015-11-16 | 2024-03-05 |
| Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Laboratory Biomarker Analysis, Pazopanib Hydrochloride - Extra-Adrenal Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 7 | 2011-05-01 | 2017-09-21 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma | Phase 1 | Completed | University of Southern California | 19 | 2010-06-01 | 2016-06-13 |
| Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors vorinostat, temozolomide, diagnostic laboratory biomarker analysis - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-02-01 | 2013-05-03 |
| RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid RAD001 - Pheochromocytoma, Extra-adrenal Paraganglioma | Phase 2 | Completed | Seoul National University Hospital | 33 | 2008-07-01 | 2015-05-20 |
Pheochromocytoma (8) · Neoplasm Metastasis (4) · Paraganglioma (3) · Carcinoma, Medullary (2) · Astrocytoma (1) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Islet Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Choroid Plexus Neoplasms (1) · Endometrial Neoplasms (1)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Nerve Tissue (10) · Neuroectodermal Tumors (10) · Neuroendocrine Tumors (10) · Paraganglioma (7) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Carcinoma (2) · Carcinoma, Neuroendocrine (2) · Neoplasms by Site (2)
Temozolomide (2) · lenvatinib (2) · Absorptiometry, Photon (1) · Everolimus (1) · Restraint, Physical (1) · Sirolimus (1) · Vinorelbine (1) · Vorinostat (1) · anlotinib (1) · cabozantinib (1) · pazopanib (1) · penpulimab (1) · temsirolimus (1)
Peking Union Medical College Hospital (4) · National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Seoul National University Hospital (1) · University of Southern California (1)
United States (5) · China (4) · Canada (1) · Hong Kong (1) · Singapore (1) · South Korea (1)
Anli Tong (4) · Agustin Garcia (1) · Ashish Chintakuntlawar (1) · Do-Youn Oh, MD, PhD (1) · Keith Bible (1) · Naifa L Busaidy (1) · Trent Hummel (1) · Yung-Jue Bang, MD, PhD (1)
PMID 23554030, PMID 29138385, PMID 29962874, PMID 31985457
P30CA015083 (2), N01CM00039 (1), N01CM00099 (1), N01CM62205 (1), U01CA097452 (1)